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Investiture of Clean Room Pharmacy, Epito-
mize USP Chapter <797> Pharmaceutical 
Compounding
Gul Ambreen, Senior  Pharmacist
Hospital acquired infections are great burden on healthcare economy and 
a direct threat to patient safety. In year 2002, Department of Pharmacy 
Services, AKUH was the pioneer in the country to start an intravenous (IV) 
admixture program whereby injectable medicines were dispensed in ready to 
use, standardized fashion following aseptic techniques of preparation. This 
has only saved a great deal of nursing time for patient care activities, but also 
streamlined many issues and concerns like inconsistent dilution and diluents 
use practice. This program has virtually eliminated certain dilution and 
concentration related Adverse Drug Reactions (ADRs) e.g. Redman Syndrome 
caused by Vancomycin. 
To take the service to new heights of professional norms and best practices, 
19th February 2014, marked the inauguration of New Clean Room Pharmacy 
specially designed as per ISO classes and United States Pharmacopoeia (USP 
<797>) standards. Equipped with High Efficiency Particulate Air (HEPA) 
filters (remove 99.97% of all air particles with size ≥ 0.3microns) and improved 
personnel and work flow through the area, this area will further enable us to 
have enhanced quality of sterile products admixture and compounded in this 
area. 
Inauguration of the area by President Mr. Feroz 
Rasool along with Mr. Nadeem Mustafa Khan, 
Dr Nadeem Ahmed  and Mr. Abdul Latif Sheikh.
IV Admixture Service – Department of 
Pharmacy Services AKUH.
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2014 Evidence-Based Guideline for the Management of High Blood 
Pressure in Adults: Eighth Joint National Committee (JNC 8)
Dr. Hafsah M Ashfaq, Pharmacist
Guideline Summary:
Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal 
failure, and death if not detected early and treated appropriately. Patients want to be assured that Blood Pressure (BP) 
treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the 
best scientific evidence.
The Eight Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 8) in adults was published in December 2013. 
Compared to the JNC-7 report, the new guidelines in name of JNC-8 are more evidence-based and use more 
“relaxed” thresholds for treatment. The JNC-8 calls for treatment to lower blood pressure (BP) to 150/90 mm Hg 
in those ages 60 and older, and to 140/90 for adults less than 60. In the population age 18 and older with diabetes, 
the guidelines recommends initiating drug treatment to a goal of systolic BP<140mmHg, and a diastolic goal of 
<90mmHg. The same applies to patients with chronic kidney disease (CKD). In general the non-black population, 
including those with diabetes, the initial antihypertensive treatment should include either a 
Thiazide or Calcium channel blocker (CCB) or Angiotensin-converting enzyme inhibitor 
(ACEI) or Angiotensin receptor blocker (ARB). In general, the black population, including those 
with diabetes, initial antihypertensive treatment should include thiazide-type diuretic or CCB. 
In adults with CKD, initial (or add-on) antihypertensive treatment should include an ACEI or 
ARB to improve kidney outcomes. This applies to all CKD patients with hypertension regardless 
of race or diabetes status. As with all consensus, guidelines that provides evidence-based 
recommendations to providers is a useful starting point. However, patients need to be monitored 
for clinical response, drug regimens  should be individualized and dosages titrated. 
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Anticoagulation Clinic - 
Enhancing Patient Care
Dr. Nida Najmi, Specialized Anticoagulation Pharmacist.
Anticoagulants (blood thinners) are used to treat 
and prevent certain medical conditions such as 
Deep vein thrombosis(DVT), PE, valvular heart 
disease, hereditary clotting disorders and atrial 
fibrillation, etc can contribute in 
major adverse drug events if not 
used correctly or used without 
proper medical advice. Due to the 
complex dosing, requisite follow-
up monitoring, and inconsistent 
patient compliance, the Joint 
Commission outlined the National 
Patient Safety Goal related to 
anticoagulation therapy (03.05.01) 
in January 1, 2009.
In order to track patients closely, help ensure 
follow-up and provide quality care with ongoing 
education to patients receiving anticoagulation 
therapy, the Department of Pharmacy took a lead 
in monitoring the use of Warfarin in hospital 
setting; and later on in collaboration with oncology/
hematology department the first ever formal 
Anticoagulation Management Clinic in the 
country has launched.
The Anticoagulation Management 
Clinic is a specialized clinic 
in which the multidisciplinary 
team (Hematologist, Specialized 
Anticoagulation Pharmacist & 
Nurse) focuses on the monitoring 
and education of the patients 
receiving anticoagulation therapy. 
This clinic is held twice a week in 
Ibn-e-Zuhr building and accepts 
Ale zehra, Clinical  Pharmacist
Vote of Thanks to all the Physicians, Nurses & Pharmacists who 
spared some time and reported Adverse Drug Reaction (ADR).
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referrals from all services and follows patients in 
clinic, ER and over the phone if required. 
As part of an Anticoagulation Management Service 
(AMS), Anticoagulation pharmacists provide 
a continuum of care for both inpatients as well 
as ambulatory patients. However, monitoring, 
prescribing and follow-up can require close 
integration between patient, lab, physician and 
pharmacist.
The clinic also provides the necessary education 
material as well as facilities like rapid point of care 
INR testing in order to cut off the waiting time and 
increase compliance of the patients towards their 
medication plan. 
The outcomes of this clinic are; the attainment 
of time in therapeutic range, increase in patient 
compliance, decrease the burden from the primary 
physician, organized system to follow-up, rapid 
& reliable INR monitoring, systemic monitoring, 
and significant decrease in thrombotic/bleeding 
events, cost effective & coordinated care, proper 
documentation and ongoing education. Total 
number of patients counseled in Year 2012 was 178 
(Jan -Dec 2012) while the total number of patients 
counseled in Year 2013 was 169 (Jan -Oct 2013) 
as shown in graph 01. Total no. of 15 patients got 
registered to anticoagulation clinic from March to 
August 2013. In which one patient had thrombotic 
event and one patient had a bleeding event but 
these adverse reactions were unrelated to Anti-
coagulation therapy lead to 100 per cent  patient 
related outcomes (Graph 02).
Graph 01:
Graph 02:
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Special Features of the Clinic:
l  Maintain warfarinised patients in 
 therapeutic range as measured  
 by INR levels
l  Minimise adverse events   
 associated with anticoagulation  
 therapy
l  Provide patients with educational
 supplements regarding   
 anticoagulation do’s and dont’s
l  Issue and maintain an anticoagulant
 treatment record book for each  
 patient
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Clinical Quality and Patient 
Safety Indicators 
Muhammad Zeeshan Khan, Pharmacist.
The quality indicators are measures of hospital 
quality and safety drawn from readily available 
hospital inpatient data. Hospital use Quality 
Indicators (QIs) to identify potential concerns about 
quality and safety and track their performance 
over time. The indicators to which Drug & Poison 
Information Centre, Department of Pharmacy 
Services, AKUH uses to track performance 
includes:
l Renal Dose Adjustment.
l Carbapenem Interchange policy.
l IV to PO Switch.
l Therapeutic Drug Monitoring (TDM) of narrow  
 therapeutic index drugs.
l ADR identification through Triggers & Markers.
Pharmacists perform these activities daily and 
intervene according to recommendation from 
different guidelines & resources. Below is the 
graphical representation of the last year data:
l Renal Dose Adjustment: Kidneys are the 
 major route of elimination for most of the drugs.  
 In patients with renal impairment, CKD or AKI   
 accumulation of drug metabolites can cause 
 adverse drug reactions, so the dosages must be   
 adjusted according to renal function. 
 Method: Patient having deranged creatinine 
 values are reviewed on a daily basis and 
 medicine doses are adjusted according to 
 creatinine clearance. In the year 2013 Antibiotics  
 were the major drug class that required 
 renal adjustment as per serum creatinine;  
 while pharmacist intervention acceptance rate
 by physicians remained to be 100 per cent.
l Carbapenem Interchange policy: Carbapenem 
 interchange policy is approved by Antibiotic  
 Subcommittee of AKUH which involves   
 switching of Meropenem to Imipenem as per 
 defined criteria. Meropenem is preferred in 
 patients who have low threshold to develop 
 seizures or are known epileptics, or are children. 
 While for all of the remaining patient 
 population, Imipenem is preferred as is less 
 expensive compared to Meropenem and equally 
 effective providing same antimicrobial 
 coverage. There is a cost saving of Rs 2000/
 day with Imipenem as compared to Meropenem 
 (compared on normal doses).
 Method: All patients on Meropenem (excluding  
 pediatric patients and patients with seizures 
 issues) are reviewed and switching of 
 Meropenem to Imipenem is suggested. Below 
 graph shows the % compliance rate to the policy 
 for year 2013. (Target is 100% switch in all 
 eligible patients)
l IV to PO Switch:  Treatment with antibiotics 
 usually starts with IV route to aggressively treat 
 the infection while later on the therapy can be 
 safely switched to oral route esp. for drugs 
 having excellent oral bioavailability like 
 Flouroquinolones, Macrolides (Clindamycin 
 etc.), Proton Pump Inhibitors, Fluconazole 
 etc. This saves precious hospital resources like 
 IV drugs that are usually expensive than oral, 
 IV administration related cost and not to forget 
 the IV route related complications and    
 infections, that are potential threat to the
 patients. It also enhances patient compliance to 
 therapy. IV to Oral switch is governed by the 
 following criteria:
l At least 24-48hrs of therapy by IV route    
 completed.
l Clinical signs of improvement (e.g. declining 
 trend of WBC, neutrophils or patient being 
 afebrile).
l Patient able to take orally.
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l Severe infections like CNS Endocarditis and 
 Sepsis are exclusion to this criteria.
 Method: All patients on selected medicines are   
 reviewed in the light of criteria and those who 
 are eligible to switch are discussed with 
 physicians. The graph below shows the 
 compliance rate for the year 2013.
l Therapeutic Drug Monitoring (TDM)   
 of narrow therapeutic index drugs: Narrow 
 therapeutic index (NTI) drugs require serum 
 concentration monitoring to correlate between 
 their doses and therapeutic response. Narrow   
 therapeutic drug have narrow margin of safety 
 so it is recommended to monitor their serum 
 concentration. Drugs included in TDM are 
 Digoxin, Theophylline, Warfarin & Phenytoin. 
 Pharmacist check patients profiles and if 
 required suggest physicians to draw serum 
 levels/INR. Below graph for 2013 shows 
 the percent interventions required for doses 
 to be changed with respect to the serum drug 
 concentrations. Declining trend signifies that 
 the NTI drugs are vigilantly monitored by the 
 physicians and need of pharmacist intervention 
 to optimize doses is declining.
l ADR identification through Triggers &   
 Markers: Adverse drug reactions are either 
 voluntarily reported by healthcare staff or 
 identified through triggers and markers by 
 pharmacists. Trigger/Markers: E.g. tracking stat 
 dose of antihistamines or antidotes like 
 protamine, naloxone etc. to identify allergic 
 reaction or overdose respectively. Pharmacy 
 maintains the record of all adverse drug 
 reactions reported and on monthly basis a 
 summary of ADRs is prepared for review by 
 P&TC to take necessary action for safety. 
 Following are the numbers of ADRs reported in   
 year 2013.
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FDA Drug Safety Podcast 2013
Compiled by: Dr. Hafsah M Ashfaq, Pharmacist.
FDA Alert Date of Alert: Summary:
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FDA warns of serious skin reactions 
with the anti-seizure drug (clobazam) 
and has approved label changes
Updated recommendations to decrease 
risk of spinal column bleeding and 
paralysis in patients on low molecular 
weight heparins
•	 Clobazam should be discontinued at the first sign 
of rash. If signs or symptoms suggest a serious skin 
reaction, use of Clobazam should not be resumed.
•	 For enoxaparin, placement or removal of a spinal 
catheter should be delayed for at least 12 hours after 
administration of prophylactic doses. Longer delays (24 
hours) are appropriate to consider for patients receiving 
higher therapeutic doses of enoxaparin (1 mg/kg twice 
daily or 1.5 mg/kg once daily) while post procedure 
dose of should usually be given no sooner than 4 hours.
December 3, 
2013
November 6, 
2013
Pharmacy Newsletter
FDA requires label changes to 
warn of risk for possibly permanent 
nerve damage from antibacterial 
fluoroquinolone drugs taken by 
mouth or by injection
August 16, 2013 •	 If a patient develops symptoms of peripheral neuropathy, the fluoroquinolone should be stopped.
FDA warns of rare but serious skin 
reactions with the pain reliever/fever 
reducer acetaminophen
August 1, 2013
•	 Use of acetaminophen and NSAIDs should be 
discontinued at the first appearance of skin rash or any 
other sign of hypersensitivity.
FDA limits usage of Ketoconazole  
oral tablets due to potentially 
fatal liver injury and risk of drug 
interactions and adrenal gland 
problems
July 26, 2013
•	The use of ketoconazole tablets in Candida and dermato-
phyte and fungal infections of the skin or nails is no longer 
indicated except blastomycosis, coccidioidomycosis, his-
toplasmosis, chromomycosis, and paracoccidioidomyco-
sis in patients in whom other treatments have failed. Con-
traindicated in acute or chronic liver disease.
FDA Recommends Against 
Prolonged Use of Magnesium Sulfate 
to Stop Pre-term Labor Due to Bone 
Changes in Exposed Babies
May 30, 2013
•	Continuous administration of magnesium sulfate injection 
beyond 5 to 7 days in pregnancy for the treatment of pre-
term labor can cause low calcium levels and bone changes 
in the baby and that the safety and efficacy of use for this 
indication are not established. 
Valproate Anti-seizure Products 
Contraindicated for Migraine 
Prevention in Pregnant Women due 
to Decreased IQ Scores in Exposed 
Children.
May 6, 2013 
•	Valproate products should not be used in pregnant women 
for prevention of migraine headaches. But it should be 
used in epilepsy or bipolar disorder only if other treatments 
have failed. Increased risk for decreased IQ in fetus.
7
FDA Alert Date of Alert: Summary:
Azithromycin and the risk of 
potentially fatal heart rhythms March 12, 2013
The risk of torsades de pointes and fatal arrhythmia 
should be considered in treatment options with 
azithromycin or alternative antibacterial drugs. Groups at 
higher risk include:
•	Patients with known prolongation of the QT interval, 
a history of torsades de pointes, congenital long QT 
syndrome, bradyarrhythmias, or uncompensated heart 
failure and also patients on drugs known to prolong the 
QT interval
•	Patients with ongoing proarrhythmic conditions such as 
uncorrected hypokalemia or hypomagnesemia, clinically 
significant bradycardia, and in patients receiving Class IA 
or Class III antiarrhythmic agents.
Reference: www.fda.gov/Drugs/DrugSafety
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RENAL DOSE ADJUSTMENTS 
 
5 Easy Strides; an Expedition in CPOE 
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STRIDE 3: e.g 01        STRIDE 4: e.g 02 
 
CrCl/GFR = 18 
ml/min 
Another 
Example 
 
Click on the 
Monograph 
 
Enter the Drug 
 
Right Click on 
Weight and 
Calculator will 
Appear 
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